Advances in the Management of Myeloma

Soutar R . Myeloma overview. Scottish Medical Journal 1998; 48 (2): 38–41

Kyle R . Diagnostic criteria of multiple myeloma. In: Barlogie B , ed. Multiple Myeloma. Hematol Oncol Clin N Amer. Philadelphia: WB Saunders, 1992; 6 (2): 347–358.

Lecouvet FE , Vande BBC , Michaux L , Malghem J , Maldague BE , Jonart J , Ferrant A , Michaux JL . Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 1998; 209: 653–60.

Durie BG , Waxman AD , D'Agnolo A , Williams CM . Whole body (18)F-FDG PET identifies high risk myeloma. Journal of Nuclear Medicine 2002; 43 (11): 1457–63.

Durie BGM , Salmon SE . A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–854.

Jacobson JL , Hussien MA , Barlogie B , Durie BGM , Crowley JJ . A new staging system for multiple myeloma patients based on Southwest Oncology Group (SWOG) experience 2003; 12: 441–450.

Facon T , Avet-Loiseau H , Guillerm G , Moreau P , Genevieve F , Zandecki M , Lai JL , Leleu X , Jouet JP , Bauters F , Harousseau JL , Bataille R , Mary JY . Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2-microglobulin produce a powerful myeloma staging system for patients receiving high dose therapy. Blood 2001; 97: 1566–1571.

Chang H , Sloan S , Li D , Zhang L , Yi QL , Chen CI , Reece D , Chun K , Stewart A Keith . The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology 2004; 125 (1): 64–8.

Medical Research Council's Working Party for Therapeutic Trials in Leukaemia. Myelomatosis: Comparison of melphalan and cyclophosphamide therapy. Br Med J 1971; 1: 640–641.

Gregory WM , Richards MA , Malpas JS . Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology 1992; 10: 334–42

Attal M , Harousseau J-L , Stoppa A-M A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med 1996; 335: 91–97.

Child JA , Morgan GJ , Davies FE , Owen RG , Bell SE , Hawkins K , Brown J , Drayson MT , Selby PJ for the MRC adult leukaemia working party. High dose chemotherapy with haematopoietic stem cell rescue for multiple myeloma. N Eng J Med 2003; 348 (19); 1875–83.

Attal M , Harousseau JL , Facon T , Guilhot F , Doyen C , Fuzibet JG , Monconduit M , Hulin C , Caillot D , Bouabdallah R , Voillat L , Sotto JJ , Grosbois B , Bataille R . InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Eng J Med 2003; 349 (26): 2495–502.

Covo M , Tosi P , Zamagni E The “Bologna 96” clinical trial of single versus double autotransplants for previously untreated multiple myeloma patients. (abstract). Blood 2002; 100: 179a

Gahrton G , Svennsson H , Cavo M , Apperly J , Bacigalupo A Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haem 2001; 113 (1): 209–16.

Tosi P . Cellini C , Bonifazi F Related and unrelated allografting after myeloablative conditioning: the Bologna experience. In: Boccadoro M , Pileri A eds. Multiple Myeloma 2004. Turin, Italy; 2004, 135–136.

Salama M , Nevill T , Marcellus D . Donor leukocyte infusions for multiple myeloma. Bone MarrowTtransplant 2000; 26: 1179–84.

Maloney DG Molina AJ , Sahebi F . Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–54.

Singhal S , Mehta J , Desikan R Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 1999; 341: 1565–71.

Barlogie B , Desikan R , Eddelmon P Extended survival in advanced and refractory multiple myeloma after single agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–94.

Barlogie B , Shaughnessy J , Tricot G , Jacobson J , Zangari M , Anaissie E , Walker R , Crowley J . Treatment of multiple myeloma. Blood 2004; 103 (1): 20–32.

Richardson PG , Barlogie B , Berenson J . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Eng J Med 2003; 348: 2609–2617.

Hussein M . Trials of Arsenic trioxide in multiple myeloma. Cancer Control 2003; 10: 370–73.

Alsina M , Fonseca R , Wilson EF . The farnesyl transferase inhibitor Zarnestra is well tolerated, induces stabilisation of disease and inhibits farnesylation and oncogenic/tumour survival pathways in patients with advanced multiple myeloma. Blood 2004; 103 (9): 3271–7.

Shipman CM , Rogers MJ , Apperley JF , Graham R , Russell R , Croucher PI . Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haem 1997; 98: 665–672.

McLoskey EV , MacLennan IC , Drayson MT , Chapman C , Dunn J , Kanis JA . A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haem 1998; 100 (2): 317–25.

Berenson J , Lichtenstein A , Porter L ef al. Efficacy of Pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med 1996; 334: 488–493.

Berenson JR , Rosen Ls , Howell A . Zoledronic acid reduces skeletal-related events in patients with osteolytic lesions. Cancer 2001; 91: 1191–200.

UK Myeloma Forum on behalf of the British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haem 2001; 115: 522–40.

Lieberman I , Reinhardt MK . Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clinical Orthopaedics and Related Research 2003; 1 (415S): S176–86.

Diamond TH , Hartwell T , Clarke W , Monoharan A . Percutaneous Vertebroplasty for acute vertebral body fracture and deformity in multiple myeloma: a short report. B J Haem 2004; 124 (4): 485–487.

Bohlius J , Langensiepen S , Schwarzer G , Seidenfield J , Piper M , Bennet C , Engert A . Erythropoietin for patients with malignant disease (Cochrane review). In: The Cochrane library, Issue 3, 2004. Chichester, UK: John Wiley.